Search results for " FIBROSIS"

showing 10 items of 490 documents

Th17 cells regulate liver fibrosis by targeting multiple cell types: many birds with one stone.

2012

Cell typePathologymedicine.medical_specialtyHepatologyKupffer CellsLiver fibrosisInterleukin-17GastroenterologyBiologyLiver Cirrhosis ExperimentalArticleLivermedicineHepatic Stellate CellsAnimalsHumansSignal transductionInflammation MediatorsLiver immunologySignal TransductionGastroenterology
researchProduct

Cellular basis of abnormal tissue hardening in lung fibrosis examined with atomic force microscopy

2010

Cellular basisPathologymedicine.medical_specialtyMaterials scienceAtomic force microscopyLung fibrosisHardening (metallurgy)medicine
researchProduct

Identification and validation of novel molecules obtained by integrated computational and experimental approaches for the read-through of PTCs in CF …

2015

ChemistrySettore BIO/11 - Biologia MolecolareComputational biologyCystic Fibrosis Ataluren premature termination codon (PTC)Settore CHIM/06 - Chimica OrganicaBioinformaticsRead throughCystic fibrosis; Premature Termination codons (PTC); oxadiazoles; Ataluren (PTC124)Settore BIO/18 - GeneticaAtaluren (PTC124)Premature Termination codons (PTC)Cystic fibrosiIdentification (biology)oxadiazole
researchProduct

Spleen Tyrosine Kinase (SYK) in the Progression of Peritoneal Fibrosis Through Activation of the TGF-β1/Smad3 Signaling Pathway.

2019

BACKGROUND Long-term exposure to hypertonic and high glucose in peritoneal dialysis fluid can result in peritoneal fibrosis. Spleen tyrosine kinase (SYK) has a role in inflammation and fibrosis. This study aimed to investigate the role of SYK in an in vivo rat model of peritoneal fibrosis and in rat peritoneal mesothelial cells (PMCs) in vitro and to investigate the underlying mechanisms. MATERIAL AND METHODS Sprague-Dawley rats (N=24) were randomized into the sham control group (N=6); the peritoneal fibrosis group (N=6) treated with intraperitoneal chlorhexidine digluconate; the SYK inhibitor group (N=6), treated with chlorhexidine digluconate and fostamatinib; and the TGF-s inhibitor grou…

ChinaSykInflammation030204 cardiovascular system & hematologyPharmacologyFostamatinibRats Sprague-DawleyTransforming Growth Factor beta103 medical and health sciences0302 clinical medicineWestern blotIn vivoFibrosismedicineAnimalsSyk KinaseSmad3 ProteinPeritoneal Fibrosismedicine.diagnostic_testChemistryAnimal StudyChlorhexidinePeritoneal FibrosisGeneral Medicinemedicine.diseaseRatsDisease Models AnimalNephrology030220 oncology & carcinogenesisDisease Progressionmedicine.symptomPeritoneumPeritoneal DialysisTransforming growth factormedicine.drugSignal TransductionMedical science monitor : international medical journal of experimental and clinical research
researchProduct

The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart

2021

Nonalcoholic fatty liver disease (NAFLD) is strongly associated to the features of metabolic syndrome which can progress to cirrhosis, liver failure and hepatocellular carcinoma. However, the most common cause of mortality in people with NAFLD is not liver-related but stems from atherosclerotic cardiovascular disease (CVD). The prevalence of NAFLD is on the rise, mainly as a consequence of its close association with two major worldwide epidemics, obesity and type 2 diabetes (T2D). The exact pathogenesis of NAFLD and especially the mechanisms leading to disease progression and CVD have not been completely elucidated. Human fetuin-A (alpha-2-Heremans Schmid glycoprotein), a glycoprotein produ…

Cirrhosisalpha-2-HS-GlycoproteinQH301-705.5030209 endocrinology & metabolismReviewType 2 diabetes030204 cardiovascular system & hematologyBioinformaticsdigestive systemCatalysisInorganic ChemistryPathogenesis03 medical and health sciences0302 clinical medicineInsulin resistanceNon-alcoholic Fatty Liver DiseaseNAFLDNonalcoholic fatty liver diseaseAnimalsHumansMedicineBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologyCVD Fetuin‐A NAFLD Animals Cardiovascular Diseases Fibrosis Humans Liver Non-alcoholic Fatty Liver Disease alpha-2-HS-GlycoproteinSpectroscopybusiness.industryOrganic Chemistrynutritional and metabolic diseasesGeneral MedicineCVDmedicine.diseaseFibrosisObesitydigestive system diseasesFetuin-AComputer Science ApplicationsChemistryLiverCardiovascular DiseasesHepatocellular carcinomaMetabolic syndromebusinessInternational Journal of Molecular Sciences
researchProduct

Gender differences in chronic HBsAg carriers in Italy: Evidence for the independent role of male sex in severity of liver disease

2015

It has been shown that sexual hormones have an opposite effect on hepatic fibrosis progression and hepatocellular carcinoma development. Sex differences among 2,762 chronic HBsAg carriers consecutively referring Italian hospitals in 2001 and in 2007 have been evaluated, particularly focusing on the role of gender on severity of liver disease. The overall sex ratio (males/females) was 2.6. Females were more likely born abroad and new diagnosis cases; but less likely HIV coinfected. No sex difference was observed regarding coinfection with other hepatitis viruses. The sex ratio linearly increased with increasing severity of liver disease, being 1.3 in normal ALT, 2.8 in chronic hepatitis, 3.6…

Cirrhosisbusiness.industryHepatitis Bmedicine.diseaseVirologydigestive system diseasesVirusLiver diseaseInfectious DiseasesVirologyHepatocellular carcinomamedicineCoinfectionHepatic fibrosisbusinessSex ratioJournal of Medical Virology
researchProduct

Roflumilast Prevents the Metabolic Effects of Bleomycin-Induced Fibrosis in a Murine Model

2015

Fibrotic remodeling is a process common to chronic lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, acute respiratory distress syndrome and asthma. Based on preclinical studies phosphodiesterase 4 (PDE4) inhibitors may exhibit beneficial anti-inflammatory and anti-remodeling properties for the treatment of these respiratory disorders. Effects of PDE4 inhibitors on changes in the lung metabolome in models of pulmonary fibrotic remodeling have not yet been explored. This work studies the effects of the PDE4 inhibitor roflumilast on changes in the lung metabolome in the common murine model of bleomycin-induced lung fibrosis by nuclear magnetic resonance (…

CyclopropanesMalePathologymedicine.medical_specialtyMagnetic Resonance SpectroscopyPulmonary Fibrosislcsh:MedicineAminopyridinesPharmacologyBiologyBleomycinBleomycinMicechemistry.chemical_compoundFibrosisPulmonary fibrosismedicineMetabolomeAnimalsRespiratory systemlcsh:ScienceLungRoflumilastCOPDMultidisciplinaryLunglcsh:Rmedicine.diseaserespiratory tract diseasesMice Inbred C57BLDisease Models Animalmedicine.anatomical_structurechemistryBenzamidesMetabolomelcsh:QResearch Articlemedicine.drugPLOS ONE
researchProduct

Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury

2009

Mandarin translation of abstract Background and purpose:  The effects of a phosphodiesterase 4 (PDE4) inhibitor, roflumilast, on bleomycin-induced lung injury were explored in ‘preventive’ and ‘therapeutic’ protocols and compared with glucocorticoids. Experimental approach:  Roflumilast (1 and 5 mg·kg−1·d−1, p.o.) or dexamethasone (2.5 mg·kg−1·d−1, p.o.) was given to C57Bl/6J mice from day 1 to 14 (preventive) or day 7 to 21 (therapeutic) after intratracheal bleomycin (3.75 U·kg−1). In Wistar rats, roflumilast (1 mg·kg−1·d−1, p.o.) was compared with methylprednisolone (10 mg·kg−1·d−1, p.o.) from day 1 to 21 (preventive) or from day 10 to 21 (therapeutic), following intratracheal instillatio…

CyclopropanesMalemedicine.medical_specialtyPhosphodiesterase InhibitorsPulmonary FibrosisAminopyridinesLung injuryBiologyBleomycinBronchoalveolar Lavagechemistry.chemical_compoundBleomycinMiceFibrosisRight ventricular hypertrophyInternal medicinePulmonary fibrosismedicineAnimalsRats WistarLungDexamethasoneRoflumilastPharmacologymedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionLung Injuryrespiratory systemmedicine.diseaseResearch Papersrespiratory tract diseasesRatsMice Inbred C57BLDisease Models AnimalBronchoalveolar lavageEndocrinologychemistryBenzamidesPhosphodiesterase 4 InhibitorsBronchoalveolar Lavage Fluidmedicine.drug
researchProduct

The role of attachment patterns and family functioning on psychophysical well-being in children with Cystic Fibrosis Preliminary Results

2013

(1) Introduction Scientific literature evidences a link between the quality of personal relationships and health status: the attachment style has a role on health and growth outcomes (Feeney, 2000) especially in chronic illness representing a threatening situation (Ciechanowski, 2003). Cystic fibrosis (CF) is a chronic genetic condition compromising the exocrine glands functioning and requiring intensive daily therapies (White et al., 2009). In pediatric condition, infant-mother relationship constituted an important element for nutritional status in CF children (Simmons et al., 1995; Anthony et al. 1999) which is one of the major factors contributing to improve longevity and quality of life…

Cystic Fibrosis attachment psychophysical well-being
researchProduct

Furocoumarins as multi-target agents in the treatment of cystic fibrosis.

2019

Multi-target molecular entities, offer a path to progress both in understanding causes of disease and in defining effective small molecule treatments. Coumarin and its derivatives belong to an important group of natural compounds with diverse biological properties. They are found in vegetables and plants for which literature reports thousands of publications for the great variety of biological applications among which the photoprotective effects, thus being considered multi-targeting agents. Their furan condensed analogues constitute the family of furocoumarins, less represented in the literature, endowed with photosensitizing properties and often used for the treatment of skin diseases suc…

Cystic FibrosisFurocoumarinComputational biologyCystic fibrosisStructure-Activity RelationshipMulti targetCoumarinsBiological propertyFurocoumarinsDrug DiscoverymedicineCystic fibrosis (CF)HumansCFTR modulatorPharmacologyDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryGeneral Medicinemedicine.diseaseCFTR modulatorsMulti-target agentsSmall moleculeFurocoumarinsCFTR modulators; Cystic fibrosis (CF); Furocoumarins; Multi-target agentsEuropean journal of medicinal chemistry
researchProduct